Neoadjuvant immunotherapy with relatlimab and nivolumab is safe and effective in stage III melanoma

Cancer-seeking molecular delivery system could boost immunotherapy drug

Cancer biomarker data is not diverse, with implications for immunotherapy patients from underrepresented groups

Advanced melanoma survival improves significantly when immunotherapy is given before targeted therapy